Tissue Engineering: Muscling in on the third dimension
When building a house, ‘framing’ involves fitting together wooden or steel supports to give the house shape and to establish the dimensions of the space within it. The extracellular matrix—a dense web of proteins—serves a similar scaffolding role for tissues in the body. And having height, width and depth also really matters when it comes to tissues.
In the laboratory it is common to grow cells in a single two-dimensional layer on a plastic culture dish. This strategy has expanded our understanding of cells, but has often failed to lead to new therapies to treat the diseases and disorders that can afflict our tissues. In contrast, three-dimensional culture models of human skin, lung, cardiac tissue and liver faithfully mimic the responses of living tissue, and can be used to predict how these tissues might respond to potential therapies (Bhatia and Ingber, 2014). This is because being three-dimensional provides tissue with stability, acts as a scaffold for repair, and even seems to be involved in the progression of certain diseases (Pampaloni et al., 2007; Lancaster and Knoblich, 2014). It is not a surprise that there is a push within the tissue-engineering community to establish three-dimensional culture models of each and every human tissue.
Skeletal muscle is the most abundant tissue in the human body and is needed for moving limbs, blinking, swallowing, breathing and maintaining a constant body temperature. It is composed of many muscle cells that are aligned with one another and embedded within an extracellular matrix scaffold. Human muscle cells form as a result of many single cells fusing with one another to create a single long cylinder; this process was first recreated in two-dimensional culture dishes in the early 1980s (Blau and Webster, 1981). However, skeletal muscle contracts in response to electrical signals from the brain, and it has been notoriously difficult to grow human muscle fibers that have this property.
Now, in eLife, Nenad Bursac of Duke University and colleagues—including Lauran Madden as first author—report the first three-dimensional culture model of human skeletal muscle that responds to electrical and biochemical stimulation just like the real thing (Madden et al., 2015). First, Bursac, Madden and co-workers placed human muscle cells (which had been collected from biopsies of patients) in a two-dimensional culture dish and allowed them to undergo many rounds of cell division (Figure 1). They then mixed the cells into a protein-rich scaffold and transferred the mixture into a custom-made silicone rubber mold where it formed a soft porous gel (similar to jello [US] or jelly [UK]). A nylon frame included in the mold provided two attachment points for the gel, mimicking the sites where skeletal muscle attaches to bone via tendons. Within just two weeks, the cells had fused together to form long aligned muscle fibers. What's more, these muscle fibers could twitch and contract!
Prior attempts by other researchers using similar devices to mimic tendons had failed to contract in response to electrical stimulation (Powell et al., 2002; Chiron et al., 2012). The secret to success seems to be in the list of ingredients used to make the protein-rich scaffold. Most laboratories had previously used collagen, a protein that is abundant in skeletal muscle. However, Madden et al. used fibrin—a product of blood clotting found in skeletal muscle undergoing repair—and found that it worked better. Fibrin had previously been shown to also be the best choice for engineering three-dimensional muscle from mouse muscle cells (Hinds et al., 2011).
Madden et al. went on to show that, when stimulated electrically or chemically, the engineered skeletal muscle responds much like normal tissue: first it releases calcium ions (Ebashi and Endo, 1968) and then it starts twitching. Furthermore, three classes of pharmaceutical drugs had similar effects on the engineered muscle as they do on normal muscle tissue in clinical settings. These results validate the potential application of the engineered skeletal muscle as a preclinical platform for drug testing.
Skeletal muscle has an amazing capacity for repair due to the presence of a small population of stem cells residing within the tissue (Mauro, 1961). However, muscle mass and function can be lost as result of degenerative conditions, like aging, and genetic conditions, such as Duchenne muscular dystrophy. The availability of a three-dimensional model of human skeletal muscle provides hope for the identification of new drugs that improve muscle strength in a diverse range of clinical settings. Moreover, it opens the door to the possibility of creating muscle tissue in a dish from a patient's own cells and then using this model to identify the most effective treatment for the patient's condition: so-called skeletal muscle personalized medicine.
With every scientific advance come new challenges. It is still unclear whether the culture system developed by Madden et al. is suitable for modeling disorders such as Duchenne muscular dystrophy. Furthermore, for pharmaceutical companies to switch to a three-dimensional tissue model, the new model must first uncover important biological findings that are obscured in standard two-dimensional cultures. And in order to integrate the new culture device with high-throughput drug screening platforms, it will be necessary to make it smaller, while also establishing simple, cost-effective metrics that can rapidly assess health of the tissue. Regardless, the advance by Bursac, Madden and co-workers has pushed the field one step closer to achieving the goal of maintaining muscle strength and health throughout life.
References
-
Isolation and characterization of human muscle cellsProceedings of the National Academy of Sciences of USA 78:5623–5627.https://doi.org/10.1073/pnas.78.9.5623
-
Calcium and muscle contractionProgress in Biophysics and Molecular Biology 18:123–183.https://doi.org/10.1016/0079-6107(68)90023-0
-
Satellite cell of skeletal muscle fibersJournal of Biophysical and Biochemical Cytology 9:493–495.https://doi.org/10.1083/jcb.9.2.493
-
The third dimension bridges the gap between cell culture and live tissueNature Reviews Molecular Cell Biology 8:839–845.https://doi.org/10.1038/nrm2236
-
Mechanical stimulation improves tissue-engineered human skeletal muscleAmerican Journal of Physiology - Cell Physiology 283:C1557–C1565.https://doi.org/10.1152/ajpcell.00595.2001
Article and author information
Author details
Publication history
Copyright
© 2015, Afshar Bakooshli and Gilbert
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 2,023
- views
-
- 217
- downloads
-
- 3
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Developmental Biology
- Stem Cells and Regenerative Medicine
A major challenge in the stem cell biology field is the ability to produce fully functional cells from induced pluripotent stem cells (iPSCs) that are a valuable resource for cell therapy, drug screening, and disease modelling. Here, we developed a novel inducible CRISPR-mediated activation strategy (iCRISPRa) to drive the expression of multiple endogenous transcription factors (TFs) important for in vitro cell fate and differentiation of iPSCs to haematopoietic progenitor cells. This work has identified a key role for IGFBP2 in developing haematopoietic progenitors. We first identified nine candidate TFs that we predicted to be involved in blood cell emergence during development, then generated tagged gRNAs directed to the transcriptional start site of these TFs that could also be detected during single-cell RNA sequencing (scRNAseq). iCRISPRa activation of these endogenous TFs resulted in a significant expansion of arterial-fated endothelial cells expressing high levels of IGFBP2, and our analysis indicated that IGFBP2 is involved in the remodelling of metabolic activity during in vitro endothelial to haematopoietic transition. As well as providing fundamental new insights into the mechanisms of haematopoietic differentiation, the broader applicability of iCRISPRa provides a valuable tool for studying dynamic processes in development and for recapitulating abnormal phenotypes characterised by ectopic activation of specific endogenous gene expression in a wide range of systems.
-
- Neuroscience
- Stem Cells and Regenerative Medicine
Parkinson’s disease (PD) is a multifactorial disease caused by irreversible progressive loss of dopaminergic neurons (DANs). Recent studies have reported the successful conversion of astrocytes into DANs by repressing polypyrimidine tract binding protein 1 (PTBP1), which led to the rescue of motor symptoms in a chemically-induced mouse model of PD. However, follow-up studies have questioned the validity of this astrocyte-to-DAN conversion model. Here, we devised an adenine base editing strategy to downregulate PTBP1 in astrocytes and neurons in a chemically-induced PD mouse model. While PTBP1 downregulation in astrocytes had no effect, PTBP1 downregulation in neurons of the striatum resulted in the expression of the DAN marker tyrosine hydroxylase (TH) in non-dividing neurons, which was associated with an increase in striatal dopamine concentrations and a rescue of forelimb akinesia and spontaneous rotations. Phenotypic analysis using multiplexed iterative immunofluorescence imaging further revealed that most of these TH-positive cells co-expressed the dopaminergic marker DAT and the pan-neuronal marker NEUN, with the majority of these triple-positive cells being classified as mature GABAergic neurons. Additional research is needed to fully elucidate the molecular mechanisms underlying the expression of the observed markers and understand how the formation of these cells contributes to the rescue of spontaneous motor behaviors. Nevertheless, our findings support a model where downregulation of neuronal, but not astrocytic, PTBP1 can mitigate symptoms in PD mice.